Si-Bone, Inc.
A maker of titanium and bone implants for the sacroiliac (SI) joint, where the spine meets the pelvis. Its iFuse line of triangular, 3D-printed titanium implants is used in minimally invasive surgery to fuse that joint and ease lower-back and pelvic pain. Founded in 2008 by orthopedic surgeon Dr. Mark Reiley, who also invented kyphoplasty, the company's name simply nods to its focus: "SI" stands for sacroiliac.
10-Q · Quarter ended Jun 30, 2026 · SEC filing ↗
growth decelerated to 15.2%, the slowest second-quarter pace since at least 2022. Revenue reached $56.0 million and slipped 0.3 points to 79.5% as a 14.9% increase in U.S. procedure volumes was partly offset by product mix pressure. The company remains on a path toward operating breakeven, but the growth rate is now half what it was two years ago.
Q2 FY2026 revenue rose 15.2% to $56.0M on 14.9% U.S. procedure volume growth, while gross margin dipped slightly to 79.5%.
Foreign-currency and interest-rate risks are disclosed, with no material sensitivity to hypothetical 100bp shifts in either rates or FX.
The information regarding legal proceedings set forth under “Legal Contingencies” in Note 6, Commitments and Contingencies, to our unaudited condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q is incorporated herein by ref…
The information regarding legal proceedings set forth under “Legal Contingencies” in Note 6, Commitments and Contingencies, to our unaudited condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q is incorporated herein by reference. 30
Read original filing text →There have been no material changes from the risk factors previously disclosed in Part I, Item 1A. “Risk Factors” of our 2025 Annual Report. The risk factors described in our 2025 Annual Report, as well as other information set forth in this Quarterly Report on Form 10-Q, could…
There have been no material changes from the risk factors previously disclosed in Part I, Item 1A. “Risk Factors” of our 2025 Annual Report. The risk factors described in our 2025 Annual Report, as well as other information set forth in this Quarterly Report on Form 10-Q, could materially adversely affect our business, financial condition, results of operations and prospects, and should be carefully considered. The risks and uncertainties that we face, however, are not limited to those described in the 2025 Annual Report. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business and the trading price of our securities.
Read original filing text →